Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

Jonathan D Schoenfeld and colleagues' phase 2 trial1 from the US National Cancer Institute is a thought-provoking trial that adds much-needed randomised data to the nascent topic of combining radiotherapy and immunotherapy for metastatic non-small-cell lung cancer (NSCLC). However, several clarifications regarding the applicability of this trial require further attention.